Navigation Links
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Date:12/5/2012

lastic Syndromes (MDS)

  • Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
    Lead Author: Hagop M. Kantarjian, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
    Abstract No. 421
    Oral Presentation: Monday, Dec. 10, 10:30 a.m. – 12:00 p.m. EST, B216-B217, Level 2, Building B

 

  • Development and Validation of a Model to Predict Response to Romiplostim in Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Placebo-controlled Study
    Lead Author: Mikkael A. Sekeres, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
    Abstract No. 2801
    Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B

Febrile Neutropenia Data

  • Clinical and Economic Burden During Hospitalizations Among Cancer Patients with Febrile Neutropenia: Evidence From U.S. Hospitals, 2007-2010
    Lead Author: Brian Dulisse, Premier Healthcare Alliance, Charlotte, NC
    Abstract No. 239
    Oral Presentation: Sunday, Dec. 9, 4:30 p.m. – 6:00 p.m. EST, C211-C213, Level 2, Building C

About Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The disease progresses rapidly and affects immature blood cells, rather than mature ones.1 Worldwide, ALL accounts for more than 12 percent of leukemia. Of the 42,000 people diagnosed worldwide, 31,000 will die from the disease.
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
3. Amgen Announces 2012 Third Quarter Dividend
4. Amgen to Present at the Leerink Swann Global Healthcare Conference
5. Amgen to Acquire Micromet
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
8. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
9. Amgen Announces 2012 First Quarter Dividend
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Ky. (PRWEB) March 03, 2015 Experts ... their schedules for one event: the Alltech REBELation exploring ... from May 17-20. Now in its 31st year, Alltech’s ... from 70 countries, and the opportunity to join the ... March 7 at 11:59 p.m. EST, at which point ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for odour control projects in North America ... Asia . "Bidding activity in 2015 continues to ... "After a high volume year for bidding in 2014, we are ... The recent orders reflect the organization,s renewed focus on select market ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... "Gene Therapy Market, 2015 - 2025" report ... Market, 2015-2025" report provides an extensive study on the ... has been carried out in this field for over ... (four available in Asian markets; one approved in the ...
(Date:3/3/2015)... , March 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... Gorman , President and Chief Executive Officer of Neurocrine ... Conference in Miami.   The live presentation ... (7:15am PT).  The presentation will be webcast and may ... .   Listeners are encouraged to visit ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... , ... therapeutics company, announces that the first clinical center in the,US, ... the phase III clinical study of Alpharadin in men with,castration-resistant ... the skeleton. , The ALSYMPCA (ALpharadin ...
... Dec. 11 Gwathmey, Inc., a pre-clinical contract ... aureus, and cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... with small businesses and the federal government. Prior ...
... ... announces the opening of a NEW 2nd North American facility in Marietta, OH. The facility ... the North American market, specifically in the area of New Product Introductions (NPI) for temperature-controlled ... Hatboro, PA ...
Cached Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)...  Businesses have a new option for premier ... Enterprises has announced the launch of a brand ... businesses to protect their customers, personal data, as ... Beconux is a biometric transaction processing system recently ... an ATM machine, the new system fuses multiple ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2
... , The President of the Deutsche Forschungsgemeinschaft (DFG, ... decision by the German Federal Parliament on the Stem ... grateful for the decision taken by Parliament. We are ... towards the critical debate of the issue. The ...
... the green off the potatoes. Any child would know ... idea. The reason behind this is that they contain ... the consumer. Each night, tropical fruit-eating bats ingest ... This may become particularly problematic for pregnant or lactating ...
... researchers from around the world will present the latest ... waves at the 2008 Conference on Lasers and Electro-Optics/Quantum ... at the San Jose McEnery Convention Center in San ... for those in the lasers and electro-optics community. It ...
Cached Biology News:Why fruit-eating bats eat dirt 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 3Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 4Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 6Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 7
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
Prepared in distilled water....
in vitro Translation, Accessory Products...
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
Biology Products: